Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04766684
Other study ID # 200842
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 1, 2021
Est. completion date January 1, 2026

Study information

Verified date October 2023
Source Vanderbilt University Medical Center
Contact Brooke Turner
Phone 615-936-1357
Email brooke.turner@vumc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infants undergoing Ponseti treatment for idiopathic clubfoot often require percutaneous tendoachilles lengthening (TAL) after serial casting. This procedure is commonly performed in the office with a local anesthetic to avoid exposure to general anesthesia in the operating room. Topical anesthetic creams are commonly used to provide local analgesia for this procedure. The cream is applied to the infant's skin around the heel cord and requires 30-60 minutes to provide adequate analgesia, reaching a depth of up to 5 mm at maximum effect. Alternative to analgesic cream, the J-tip is a needle-free jet injection system that uses compressed CO2 instead of a needle to push 0.25 ml of lidocaine into the skin, providing local analgesia at the site of administration. This method likewise provides analgesia to the site of application at a depth of 5-8 mm, yet only takes approximately 1-2 minutes to achieve maximum effect. Aim 1: Determine which pain management method, L.M.X.4 Cream vs. J-tip 1% Xylocaine MPF Injection, provides the greatest pain relief to infants with clubfoot undergoing an in-office percutaneous TAL. Hypothesis: J-tip 1% Xylocaine MPF injection will provide equal or greater pain control when compared to L.M.X.4 cream in infants undergoing an in-office percutaneous TAL. Aim 2: Determine if there is a difference in the rate of adverse events between the two pain management methods, L.M.X.4 Cream vs. J-tip 1% Xylocaine MPF Injection. Hypothesis: J-tip 1% Xylocaine MPF injection will not be associated with an increased rate of adverse events in comparison to L.M.X.4 cream in infants undergoing an in-office percutaneous TAL. If J-tip Xylocaine MPF injection is shown to provide comparable or better pain control without an increase in adverse events, use of this needle-free injection system will decrease the overall length of visit and the cost of the procedure, thus increasing the quality, safety, and value.


Description:

Clubfoot is a common congenital birth deformity, with a prevalence of 1 in 1000 live births. If left untreated, clubfoot can cause significant disability. Treatment of clubfoot has evolved over several decades and now favors the method of serial casting pioneered by Ignacio Ponseti. This technique involves weekly stretching followed by application of a long leg cast. In the majority of cases, percutaneous tendoachilles lengthening (TAL) is required to correct the equinus component of the clubfoot deformity. Following TAL, a long leg cast is applied for 3 weeks and then a foot-abduction orthosis is utilized to maintain correction of the deformity. Percutaneous TAL can be performed in the operating room under general anesthesia or in an outpatient setting utilizing local or topical anesthesia. While studies have shown that in-office percutaneous TAL is safe and efficient, little has been done to investigate the pain management strategies implemented for infants during this procedure. Pain management for infants during procedures is important because it has been shown that repeated painful exposures during early stages of life can lead to alterations in hemodynamic stability, altered stress hormone expression, heightened peripheral sensitivity, altered pain reactivity that persists following the painful stimulus, and somatization. One study identified the infant's ability to become conditioned to painful stimuli, such as heel sticks, at as early as 3 days old. Based on this, providers should be prepared to provide adequate pain management for infants during painful procedures, such as in-office TAL, by utilizing non-pharmaceutical techniques, pharmaceutical techniques, or a combination of both. Needle injection of local anesthetic is generally avoided prior to an in-office percutaneous TAL due to the needle puncture and the concern that soft tissue swelling may prevent accurate palpation of the heel cord during the procedure. As such, topical local anesthetic creams are commonly used to provide local analgesia for this procedure. The cream is applied to the infant's skin around the heel cord and requires 30-60 minutes to provide adequate analgesia, reaching a depth of up to 5 mm at maximum effect. At our institution, a 5 gram tube of L.M.X.4 cream costs $4.12, while other studies report that a larger 25 gram tube of EMLA cream can cost as much as $56, with the excess being wasted. Alternative to anesthetic cream, the J-tip is a needle-free jet injection system that uses compressed CO2 instead of a needle to push 0.25 ml of lidocaine into the skin, providing local analgesia at the site of administration. This method provides analgesia to the site of application at a depth of 5-8 mm and takes approximately 5 minutes to achieve maximum effect. At our institution, the cost of the J-tip applicator and a 20 mL 1% lidocaine vial is $5.11. Multiple studies have demonstrated the J-Tip to provide greater pain control than other pharmaceutical options, including EMLA cream and vapocoolant ("freezy") spray. The goal of this study is to determine if the J-Tip Xylocaine MPF injection provides equal or greater pain control in clubfoot patients undergoing an in-office percutaneous TAL when compared to L.M.X.4 cream, without an increase in adverse events. If this is true, use of J-tip Xylocaine MPF injection will decrease the overall time and cost of the visit, while ultimately increasing the quality, safety, and value of in-office TAL for the treatment of clubfoot in infants.


Recruitment information / eligibility

Status Recruiting
Enrollment 94
Est. completion date January 1, 2026
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 6 Weeks
Eligibility Inclusion Criteria - Clubfoot patients less than 6 weeks of age at start of casting - Patients presenting to Vanderbilt DOT 4 Clinic for care - Patients undergoing in-clinic Achilles Tenotomy Exclusion Criteria - Clubfoot patients greater than 6 weeks of age at the start of casting - Previous clubfoot treatment - Patients with a neuromuscular condition (spina bifida, caudal regression syndrome, arthrogryposis, etc.) - In-office TAL is not recommended by treating physician due to patient factors such as age or size

Study Design


Related Conditions & MeSH terms


Intervention

Device:
J-Tip with Xylocaine MPF with placebo cream
J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream
Drug:
L.M.X.4 cream with J-Tip saline injection
L.M.X.4 cream with J-Tip saline injection

Locations

Country Name City State
United States Vanderbilt Children's Orthopaedics Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (8)

Ansar A, Rahman AE, Romero L, Haider MR, Rahman MM, Moinuddin M, Siddique MAB, Mamun MA, Mazumder T, Pirani SP, Mathias RG, Arifeen SE, Hoque DME. Systematic review and meta-analysis of global birth prevalence of clubfoot: a study protocol. BMJ Open. 2018 Mar 6;8(3):e019246. doi: 10.1136/bmjopen-2017-019246. — View Citation

COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE. Prevention and Management of Procedural Pain in the Neonate: An Update. Pediatrics. 2016 Feb;137(2):e20154271. doi: 10.1542/peds.2015-4271. Epub 2016 Jan 25. — View Citation

Herzenberg JE, Radler C, Bor N. Ponseti versus traditional methods of casting for idiopathic clubfoot. J Pediatr Orthop. 2002 Jul-Aug;22(4):517-21. — View Citation

Lebel E, Karasik M, Bernstein-Weyel M, Mishukov Y, Peyser A. Achilles tenotomy as an office procedure: safety and efficacy as part of the Ponseti serial casting protocol for clubfoot. J Pediatr Orthop. 2012 Jun;32(4):412-5. doi: 10.1097/BPO.0b013e31825611a6. — View Citation

Lunoe MM, Drendel AL, Levas MN, Weisman SJ, Dasgupta M, Hoffmann RG, Brousseau DC. A Randomized Clinical Trial of Jet-Injected Lidocaine to Reduce Venipuncture Pain for Young Children. Ann Emerg Med. 2015 Nov;66(5):466-74. doi: 10.1016/j.annemergmed.2015.04.003. Epub 2015 Apr 29. — View Citation

Morcuende JA, Dolan LA, Dietz FR, Ponseti IV. Radical reduction in the rate of extensive corrective surgery for clubfoot using the Ponseti method. Pediatrics. 2004 Feb;113(2):376-80. doi: 10.1542/peds.113.2.376. — View Citation

Spanos S, Booth R, Koenig H, Sikes K, Gracely E, Kim IK. Jet Injection of 1% buffered lidocaine versus topical ELA-Max for anesthesia before peripheral intravenous catheterization in children: a randomized controlled trial. Pediatr Emerg Care. 2008 Aug;24(8):511-5. doi: 10.1097/PEC.0b013e31816a8d5b. — View Citation

Taddio A, Shah V, Gilbert-MacLeod C, Katz J. Conditioning and hyperalgesia in newborns exposed to repeated heel lances. JAMA. 2002 Aug 21;288(7):857-61. doi: 10.1001/jama.288.7.857. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary FLACC (Face, Legs, Activity, Cry, Consolability) Scale The FLACC scale is used to assess pain in children. For this study, it will be administered by the Certified Child Life Specialist. The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain in children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. Lower values represent lessening pain on the scale Baseline, before cast placement to tenotomy procedure at the end of casting, approximately 10 weeks.
Primary Pulse Oximetry Pulse oximetry will be used to measure oxygen levels in the blood. An oxygen saturation level of 95 percent is considered normal Baseline, before cast placement to tenotomy procedure at the end of casting, approximately 10 weeks.
See also
  Status Clinical Trial Phase
Withdrawn NCT03580746 - Comparison of Ponseti Method Versus Older Treatments in Talipes Equinovarus Through Gait Analysis and Clinical Results
Completed NCT00175708 - Pedobarographic Assessments of Clubfoot Treated Patients
Recruiting NCT06050564 - Therapeutic Recommendations Based on Clinical History and Video Documented PBS-Score
Recruiting NCT06033638 - Video Documented PBS-Score in Children With Clubfoot
Recruiting NCT06050746 - Predictive Value of the PBS-score in Children With Clubfoot
Completed NCT02022267 - Gait Analysis in Ponseti Clubfoot N/A
Completed NCT01481324 - Outcomes of Compliance With Brace Wear in Clubfoot N/A
Withdrawn NCT00475631 - Economic Evaluation of Clubfoot Treatment: One Centre's Experience
Completed NCT01088828 - Exploring the Causes of Clubfoot Using Magnetic Resonance Imaging, MRI N/A
Completed NCT02815306 - Polyaxial Brace Fixing for the Treatment of Congenital Clubfoot N/A
Not yet recruiting NCT01050088 - Sucrose Analgesia in Infants Undergoing Casting for Club Foot N/A
Recruiting NCT00474032 - Using Botox to Treat Patients With Idiopathic Clubfoot N/A
Recruiting NCT04564430 - Clonidine for Tourniquet-related Pain in Children Phase 4
Recruiting NCT03249805 - MiracleFeet Foot Abduction Brace Sensor Trial N/A
Not yet recruiting NCT04737083 - CGH Array in Bilateral Clubfoot
Completed NCT02395185 - A Randomized Controlled Trial of Three Non-pharmacologic Analgesic Techniques for Casting of Clubfoot Infants N/A
Completed NCT00607191 - Clubfoot DNA Repository N/A
Completed NCT05456737 - Functional Assessment in Children With Clubfoot
Active, not recruiting NCT04693065 - Pronostic Factors of Long Term Outcome in Patients With Clubfoot Treated by the Ponseti Method
Completed NCT03953430 - Gait Analysis in Children With Clubfoot Treated With Tibialis Anterior Tendon Transfer